OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 968-977

  Ottewell, Penelope D ^a   Wang, Ning ^a   Brown, Hannah K ^a   Fowles, C Anne ^a   Croucher, Peter I ^b   Eaton, Colby L ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

bone; breast cancer; metastasis; OPG

Indexed keywords

ANTINEOPLASTIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN FC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENTS; OSTEOPROTEGERIN; RANK LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR MICROENVIRONMENT; ADVERSE EFFECTS; ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG EFFECTS; HUMANS; IMMUNOLOGY; METABOLISM; MICE; OSTEOCLASTS; PATHOLOGY; SECONDARY;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; OSTEOCLASTS; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND;

EID: 84931562264     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29439     Document Type: Article

References (37)

1. Townson JL, Chambers AF,. Dormancy of solitary metastatic cells. Cell Cycle 2006; 5: 1744-50.
2. Aguirre-Ghiso JA, Bragado P, Sosa MS,. Metastasis awakening: targeting dormant cancer. Nat Med 2013; 19: 276-7.
3. Chen YC, Sosnoski DM, Mastro AM,. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res 2010; 12: 215.
4. Clézardin P,. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011; 13: 207.
5. Coleman RE, Rathbone E, Brown JE,. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013; 9: 365-74.
6. Figueroa-Magalhães MC, Miller RS,. Bone-modifying agents as adjuvant therapy for early-stage breast cancer. Oncology (Williston Park) 2012; 26: 955-62.
7. Coleman RE, Marshall H, Cameron D, et al., Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-405.
8. Ottewell PD, Wang N, Brown HK, et al., Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 2014; 20: 2922-32.
9. Ottewell PD, Wang N, Meek J, et al., Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. End Rel Cancer 2014; 21: 769-81.
10. Ottewell PD, Deux B, Monkkonon H, et al., Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous tumour growth in vivo. Clin Cancer Res 2008; 14: 4658-66.
11. van, der Horst G, van den Hoogen C, Buijs JT, et al., Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 2011; 13: 516-25.
12. Zinonos I, Luo KW, Labrinidis A, et al., Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int J Oncol 2014; 45: 532-40.
13. Lipton A, Fizazi K, Stopeck AT, et al., Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-92.
14. Zauli G, Melloni E, Capitani S, et al., Role of full length osteoprotegrin in tumour cell biology. Cell Mil Life Sci 2009; 66: 841-815.
15. Morony S, Warmington K, Adamu S, et al., The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 3235-43.
16. Ottewell PD, Monkkonen H, Jones M, et al., Antitumour effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100: 1167-78.
17. Cole AA, Walters LM,. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold embedding in plastic. J Histochem Cytochem 1987; 35: 203-6.
18. Mucowski SJ, Mack WJ, Shoupe D, et al., Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women. Fertil Steril 2014; 101: 1117-22.
19. Liu XL, Li CL, Lu WW, et al., Skeletal site-specific response to ovariectomy in a rat model: change in bone density and microarchitecture. Clin Oral Implants Res 2014; 00: 1-7.
20. Lee SK, Kadono Y, Okada F, et al., T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006; 21: 1704-12.
21. Bellahcene A, Bachelier R, Detry C, et al., Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007; 101: 135-48.
22. Zhao H, Ning LL, Wang ZY, et al., Calcitonin gene-related peptide inhibits osteolytic factors induced by osteoblast in co-culture system with breast cancer. Cell Biochem Biophys 2014; 346: 1097-104.
23. Park HR, I, Min SK, Cho HD, et al., Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci 2003; 18: 541-6.
24. Roodman GD, Dougall WC,. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008; 34: 92-101.
25. Canon JR, Roudier M, Bryant R, et al., Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25: 119-29.
26. Body JJ,. Inhibition of RANK ligand to treat bone metastases. Bull Cancer 2013; 100: 1207-13.
27. Casas A, Llombart A, Martín M,. Denosumab for the treatment of bone metastases in advanced breast cancer. Breast 2013; 22: 585-92.
28. Gnant M, Mlineritsch B, Stoeger H, et al., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-41.
29. Thomas RJ, Guise TA, Yin JJ, et al., Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-8.
30. Miller RE, Jones JC, Tometsko M, et al., RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol 2014; 9: 345-54.
31. Canon J, Bryant R, Roudier M, et al., RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 2012; 135: 771-80.
32. Canon J, Bryant R, Roudier M, et al., Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010; 46: 1613-9.
33. Zauli G, Melloni E, Capitani S, et al., Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-51.
34. Armstrong AP, Miller RE, Jones JC, et al., RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008; 68: 92-104.
35. Vanderkerken K, De Leenheer E, Shipman C, et al., Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287-9.
36. Morony S, Capparelli C, Sarosi I, et al., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432-6.
37. Haider M-T, Holen I, Hunter K, et al., Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone 2014; 66: 240-50.